Literature DB >> 19860037

Your patient with melanoma: staging, prognosis, and treatment.

Krista M Rubin1, Donald P Lawrence.   

Abstract

Melanoma, a cancer of melanocytes, pigment-producing cells in the skin, is the most serious form of skin cancer. Its incidence is increasing rapidly and reaching epidemic proportions. When detected early, it is considered curable, but when detected at later stages it is arguably one of the most lethal malignancies and is the cause of more years of lost life than any other cancer except leukemia. Because most cutaneous melanomas are visible, however, melanoma in general is a cancer highly amenable to early detection. Surgery is standard treatment for localized melanoma. There is no standard therapy for advanced-stage melanoma. Metastatic melanoma disseminates widely and it frequently involves sites that are not commonly affected in other cancers, such as the gastrointestinal tract and skin. The median survival time for patients with metastatic melanoma is less than 1 year. Despite these grim statistics, long-term survival occurs occasionally. This article will review diagnosis, staging, and treatment for malignant melanoma and will discuss the nursing role in the care of patients with melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19860037

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  7 in total

1.  Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents.

Authors:  Evisabel A Craig; Vladimir S Spiegelman
Journal:  Pigment Cell Melanoma Res       Date:  2011-10-28       Impact factor: 4.693

2.  Enhanced anti-melanoma efficacy of interferon α-2b via overexpression of ING4 by enhanced Fas/FasL-mediated apoptosis.

Authors:  Limin Cai; Jing Liu; Yu Wang; Hongxiao Chen; Yanli Ma; Yanhua Wang; Yongchen Wang
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

Review 3.  MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy.

Authors:  Miguel F Segura; Holly S Greenwald; Doug Hanniford; Iman Osman; Eva Hernando
Journal:  Carcinogenesis       Date:  2012-06-12       Impact factor: 4.944

4.  Mediastinal and hilar sarcoid-like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature.

Authors:  Vanessa-Meletia Bala; Maria Mitsogianni; Konstantinos Laschos; Evangelia Pliakou; Eirini Lazaridi; Dimitra-Ioanna Lampropoulou; Gerasimos Aravantinos
Journal:  Mol Clin Oncol       Date:  2022-03-18

Review 5.  Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective.

Authors:  Krista M Rubin; Karen Vona; Kathleen Madden; Suzanne McGettigan; Ilana M Braun
Journal:  Support Care Cancer       Date:  2012-05-05       Impact factor: 3.603

6.  Integrative analysis of competing endogenous RNA network focusing on long noncoding RNA associated with progression of cutaneous melanoma.

Authors:  Siyi Xu; Jing Sui; Sheng Yang; Yufeng Liu; Yan Wang; Geyu Liang
Journal:  Cancer Med       Date:  2018-03-09       Impact factor: 4.452

7.  Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma.

Authors:  Yucang Shi; Zhanpeng Li; Zhihong Zhou; Simu Liao; Zhiyuan Wu; Jie Li; Jiasheng Yin; Meng Wang; Meilan Weng
Journal:  PeerJ       Date:  2022-01-21       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.